


BIOSPHERE

THE MAGAZINE OF UTAH'S LIFE SCIENCES INDUSTRY

2021
I S S U E

BEGINNINGS...
HOW IT ALL STARTED HERE



WOMEN
LEADING
LIFE SCIENCES
WHAT INSPIRES THEM

RISE



OF



GOING, GOING
GONE...PUBLIC
LIFE SCIENCES IPOs



Nasdaq



BIO



HIVE

THE BIOHIVE VISION
BOLDLY BRANDING & BUILDING THE INDUSTRY

LETTER FROM THE CHAIR

Welcome to BioUtah's 2021 Utah Life Sciences Magazine. You'll notice that our annual publication has a new name, Biosphere. The new name complements this year's theme, "The Rise of the BioHive" and reflects a new phase of opportunity, growth and visibility for Utah's vibrant life sciences industry. Biosphere will help carry that message.

We often joke that Utah's life sciences sector - one of the fastest growing in the nation - flies beneath the radar. But that's changing with BioHive— a bold new initiative, driven by BioUtah, to tell the story of the state's life sciences industry and raise its profile on the local, national and global stage.

Our feature article focuses on the vision and mission of BioHive and it's promise to both unite and ignite our expanding life sciences hub - a collective of more than 1,100 companies from Logan to St. George - all dedicated to bringing life-changing and life-saving technologies, diagnostics and therapies to patients.

Inside, we also turn a spotlight on the leaders (including inspiring women), companies, innovations and culture of entrepreneurship that, together, well-position our industry to succeed today and excel far into the future. Investors as well as our community partners are recognized. They all figure prominently in BioHive, supporting and financing startups and creating a bio-friendly business environment where cutting-edge enterprises can flourish.

In short, BioHive has arrived and we're proudly spreading the word. We invite you to turn the page to see what the "buzz" is all about!

Sincerely,





Randy Rasmussen
Chair
BioUtah Board of Directors



LIGHTING THE WAY TO SUSTAINABLE PATENCY

Alucent Biomedical was founded by the Avera Research Institute, part of the Sioux Falls, S.D.-based Avera Health System. The company is developing a revolutionary technology designed to treat peripheral artery disease (PAD).



Natural Vascular Scaffolding (AlucentNVS), uses a light-activated novel drug that links native structural proteins in the vessel wall, creating a natural scaffold, **without** the need for a permanent implant to keep vessels open. The company is also developing its AlucentNVS technology to enable patients with kidney disease receive hemodialysis through a native arteriovenous fistula.

The company relocated from South Dakota to Salt Lake City in 2017 after hiring its first full-time employee, president & CEO Dr. Myles Greenberg, who was already living in the area.

"We set up in Utah because we needed access to trained medical device and pharmaceutical personnel. We found that in abundance here. BioHive's thriving life science scene offers an amazing pool of talent with experience in the disciplines we need," Greenberg explains. "We were able to assemble a professional team with the in-depth expertise needed to accelerate Alucent's progress toward helping patients suffering from vascular disease."

675 Arapeen Drive, Suite 102, Salt Lake City, UT 84108 • AlucentBiomedical.com



PACK YOUR BAGS FOR *Utah*

THE SECRET IS OUT.

Utah is a great place to do business. Lower taxes, supportive regulatory environment, skilled workforce and a welcoming innovation hub are increasingly attracting companies to the state, including those in the life sciences.

Throw in major universities, access to the great outdoors and a host of cultural activities, and you have a winning combination that brings companies like Alucent Biomedical, Denali Therapeutics and Renalytix to Utah to work, play and prosper.



Alucent Biomedical

Utah wasn't top of mind when Alucent Biomedical was founded in Sioux Falls, South Dakota, by Avera Research Institute - part of the Sioux Falls Avera Health System. The company was focused on developing a revolutionary technology using a light-activated novel drug that would create a natural scaffold to treat peripheral artery disease (PAD), without the need for a permanent implant to keep vessels open.

Then Alucent hired Myles Greenberg, M.D., as its first full-time employee as president and CEO. Dr. Greenberg, who was already living in Utah, wanted to build a team that could take the company to the next level. But where would he find the talent he needed? The answer - right here in Utah.

"We set up in Utah in 2017 because we needed access to trained medical device and pharmaceutical personnel. We found that in abundance here - BioHive's thriving life sciences scene offers an amazing pool of talent with experience in the disciplines we need," said Greenberg. "We were able to assemble a professional team with the in-depth expertise needed to accelerate Alucent's progress toward helping patients suffering from vascular disease."

Now the company's lead product, the Vessel Restoration System with Photoactivated Linking, is starting human trials later this year. The company is also developing its Alucent NVS technology to enable patients with kidney disease to receive hemodialysis through a native arteriovenous fistula - the vascular access of choice due to longevity and lower complication rates.



Denali Therapeutics

Denali Therapeutics is also eyeing Utah to bolster its talent pool and further advance its singular, passionate mission to DEFEAT neurodegenerative disease - think Alzheimer's, Parkinson's, ALS, and Hunter syndrome. Neurodegeneration is one of the most challenging, unmet needs of our

